Exenatide monograph

Exenatide

Overview

Exenatide is a GLP-1 receptor agonist approved for type 2 diabetes management; it lowers glucose primarily by increasing glucose-dependent insulin secretion and suppressing glucagon, with slower gastric emptying and reduced appetite as additional effects (Drugs@FDA, PubMed search results). The FDA’s Drugs@FDA page identifies BYETTA (exenatide synthetic) as a subcutaneous prescription product first approved on 04/28/2005, and FDA’s written-request list also documents exenatide under AstraZeneca (Drugs@FDA, FDA written-request list). For anti-doping, exenatide/GLP-1 receptor agonists are not listed on the current WADA Prohibited List page (WADA).

Pharmacokinetics & Mechanism

• Class: GLP-1 receptor agonist (incretin mimetic; synthetic exendin-4 analogue)
• Mechanism of action: Exenatide is an exendin-4–based peptide that activates the GLP-1 receptor. In humans it enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon secretion, slows gastric emptying, and reduces food intake; the glucose-dependent nature of its insulin effect is why hypoglycemia risk rises mainly when it is combined with insulin or sulfonylureas (PubMed search results, Drugs@FDA).
• Target(s): Primary target: GLP-1 receptor (GLP1R). Downstream effects are via incretin signaling with pancreatic beta-cell insulin secretion, pancreatic alpha-cell glucagon suppression, delayed gastric emptying, and appetite/satiety pathways; no androgenic, anabolic, or direct ergogenic target is established (PubMed search results, Drugs@FDA).
• Route(s) of administration: Subcutaneous injection only for approved exenatide products (Drugs@FDA).
• Onset: Glucose-lowering effect begins after subcutaneous dosing, with postprandial effects tied to delayed gastric emptying; exact onset timing is not well established from the sources gathered here, so do not assume an oral-like rapid onset. For weekly extended-release exenatide, clinically meaningful effect is delayed by depot release and dose titration; specific onset timing is not well established in the sources captured here (PubMed search results, FDA written-request list).
• Half-life: For immediate-release exenatide (Byetta), the terminal half-life is about 2.4 hours in labeling/review literature, which supports twice-daily dosing; a peer-reviewed review specifically titled "Exenatide: pharmacokinetics, clinical use, and future directions" is identified by PubMed as the key review source (PubMed search results). Extended-release exenatide (Bydureon/Bydureon BCise) is a long-acting depot formulation with a much longer apparent release profile; exact half-life should be treated as formulation-specific and not interchangeable with immediate-release exenatide (FDA written-request list).
• Metabolism / clearance: Exenatide is a peptide drug; clearance is primarily through proteolytic degradation and renal elimination rather than CYP metabolism. Because the FDA label page content was not directly retrievable here, the most defensible statement is that it is not CYP-driven and is cleared mainly by peptide/protein catabolism with renal contribution; exact fraction-by-route details are not well established in the retrieved sources (Drugs@FDA, PubMed search results).